StockData

Vanda Pharmaceuticals vs Zevra Therapeutics

VNDA and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VNDA and ZVRA compare

Zevra Therapeutics is the larger company, worth 2.4 times as much as Vanda Pharmaceuticals ($558M against $230M).

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus 8.1% for Vanda Pharmaceuticals).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −120% at Vanda Pharmaceuticals.

Zevra Therapeutics scores higher on the StockData Score (15 against 10 for Vanda Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVNDAZVRA
Size and price
Market cap$230M$558M
Share price$3.81$9.40
Change, 1 year−12.4%5.9%
Change, 5 years−77.0%16.8%
Beta (5Y)0.781.16
Employees53361
StockData Score
Total score1015 (better)
Valuation score33
Growth score23 (better)
Performance score03 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–10.1×
P/S1.0× (better)4.1×
P/B1.2× (better)2.6×
EV/EBITDA–4.0×
P/FCF–17.1×
FCF yield−60.8%5.8% (better)
Fair value$8.53$23.57
Margin of safety55.3%60.1% (better)
Growth
Revenue growth (TTM)8.1%119% (better)
Revenue growth, 5Y average−2.7%51.6% (better)
Net income growth (TTM)–2104%
Profitability
Gross margin93.6%95.5% (better)
Operating margin−77.6%60.5% (better)
Net margin−120%42.8% (better)
FCF margin−61.0%24.0% (better)
Return on equity−82.5%34.8% (better)
Return on invested capital−52.6%–
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio1.545.17 (better)
Altman Z-score−1.854.35 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.2%78.5%
Held by insiders9.2%1.2%
Insider net buying, 12 months−$2.8M−$2.5M (better)
Short interest, % of float13.9%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.